13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports
21 July 2025. Related: Conference reports, Activism & advocacy.
IAS 13th Kigali 2025
Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results
20 July 2025. Related: Conference reports, Antiretrovirals.
IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025. Related: Conference reports, Antiretrovirals, Drug resistance.
!AS 2025: Once-monthly oral PrEP using MK-8527: the drug that will stop HIV
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: “We will not be erased” – a community Call to Action
15 July 2025. Related: Conference reports, Treatment access, Activism & advocacy.
IAS 2025: HIV care is political: early focus on the funding crisis
12 July 2025. Related: Conference reports, Treatment access.
IAS 2025: HIV cure research at IAS 2025
12 July 2025. Related: Conference reports.
IAS 2025: Kigali Call to Action: sign-on to global leaders
1 July 2025. Related: Conference reports.